CompoAtlas

Bouleau verruqueux - Macérat dynamisé

Food supplement declared in France, declaration No 2021-8-1251, decision dated 27 August 2021

Bouleau verruqueux - Macérat dynamisé (VESUNNA) is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).

Brand
VESUNNA
Food business operator placing the product on the market
VESUNNA
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Dropper
Daily dose
5 ml
Directions for use
50 à 150 gouttes par jour en 2 à 3 prises dans un peu d'eau
Not recommended (according to the manufacturer)
Allergy to salicylate derivatives, Infants (under 1 year)
Objectives stated by the manufacturer (these are not authorised claims)
Detox / Drainage, Joints

Declaration 178330, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Betula pendula RothBourgeonAutre macérât125 mg

Other active ingredients

NamePer day
miel d’acacianot declared

Other ingredients

Alcool éthylique, Eau purifiée

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Demander l'avis de votre médecin. Déconseillé aux personnes allergiques aux dérivés salicylés.Ne pas dépasser la dose journalière recommandée. Tenir hors de portée des jeunes enfants. Ne peut se substituer à une alimentation équilibrée et variée.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Betula pendula Roth
    Read the warning, when it applies and the studies cited

    Birch

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney or cardiovascular disorders (Brinker 2010; Bradley 2006; ESCOP 2003; Blumenthal et al. 1998).

    Sources cited by Health Canada (4)
    • Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Riggins C, Rister R, editors. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin (TX): American Botanical Council; 1998.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Brinker 2010).

    Sources cited by Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Health Canada monograph dated 28 August 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : VESUNNA

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line